α,β-unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells

Journal of Medicinal Chemistry

Volumn 54, Issue 2, 2011, Pages 449-456

  Bazzaro, Martina ^a   Anchoori, Ravi K ^b,c   Mudiam, Mohana Krishna R ^c   Issaenko, Olga ^a   Kumar, Srinivas ^c   Karanam, Balasubramanyam ^b   Lin, Zhenhua ^b,e   Isaksson Vogel, Rachel ^a   Gavioli, Riccardo ^d   Destro, Federica ^d   Ferretti, Valeria ^d   Roden, Richard B S ^b,c   Khan, Saeed R ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF FERRARA   (Italy)

^e YANBIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 BIS(4 BORONIC ACID BENZYLIDENE) 1 METHYLPIPERIDIN 4 ONE; BORTEZOMIB; CARBONYL DERIVATIVE; CHALCONE DERIVATIVE; PIPERIDONE DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CATALYSIS; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; NUCLEOPHILICITY; UTERINE CERVIX CANCER; WART VIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; MODELS, MOLECULAR; PAPILLOMAVIRIDAE; PROTEASOME ENDOPEPTIDASE COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE CERVICAL NEOPLASMS;

EID: 78751659623     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100589p     Document Type: Article

References (40)

1. Ciechanover, A.; Finley, D.; Varshavsky, A. The ubiquitin-mediated proteolytic pathway and mechanisms of energy-dependent intracellular protein degradation J. Cell. Biochem. 1984, 24, 27-53
2. Ciechanover, A. The ubiquitin-mediated proteolytic pathway Brain Pathol. 1993, 3, 67-75
3. Orlowski, M.; Wilk, S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex Arch. Biochem. Biophys. 2000, 383, 1-16
4. Bazzaro, M.; Lin, Z.; Santillan, A.; Lee, M. K.; Wang, M. C.; Chan, K. C.; Bristow, R. E.; Mazitschek, R.; Bradner, J.; Roden, R. B. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor Clin. Cancer Res. 2008, 14, 7340-7347
5. Bazzaro, M.; Lee, M. K.; Zoso, A.; Stirling, W. L.; Santillan, A.; Shih Ie, M.; Roden, R. B. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis Cancer Res. 2006, 66, 3754-3763
6. Curran, M. P.; McKeage, K. Bortezomib: a review of its use in patients with multiple myeloma Drugs 2009, 69, 859-888
7. Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052) Bioorg. Med. Chem. 2009, 17, 2175-2180
8. Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk, K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; van Leeuwen, F. W.; Chanan-Khan, A. A.; Orlowski, R. Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 2007, 110, 3281-3290
9. Genin, E.; Reboud-Ravaux, M.; Vidal, J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry Curr. Top. Med. Chem. 2010, 10, 232-256
10. Basse, N.; Montes, M.; Marechal, X.; Qin, L.; Bouvier-Durand, M.; Genin, E.; Vidal, J.; Villoutreix, B. O.; Reboud-Ravaux, M. Novel organic proteasome inhibitors identified by virtual and in vitro screening J. Med. Chem. 2010, 53, 509-513
11. Kaiser, M.; Groll, M.; Renner, C.; Huber, R.; Moroder, L. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition Angew. Chem., Int. Ed. 2002, 41, 780-783
12. Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.; Shimizu, R.; Ohnuki, T.; Komatsubara, S. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093 J. Org. Chem. 2000, 65, 990-995
13. Laurent, N.; de Bouard, S.; Guillamo, J. S.; Christov, C.; Zini, R.; Jouault, H.; Andre, P.; Lotteau, V.; Peschanski, M. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo Mol. Cancer Ther. 2004, 3, 129-136
14. Basse, N.; Papapostolou, D.; Pagano, M.; Reboud-Ravaux, M.; Bernard, E.; Felten, A. S.; Vanderesse, R. Development of lipopeptides for inhibiting 20S proteasomes Bioorg. Med. Chem. Lett. 2006, 16, 3277-3281
15. Dick, L. R.; Fleming, P. E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy Drug Discovery Today 2010, 15, 243-249
16. Hawley-Nelson, P.; Vousden, K. H.; Hubbert, N. L.; Lowy, D. R.; Schiller, J. T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes EMBO J. 1989, 8, 3905-3910
17. Reinstein, E.; Scheffner, M.; Oren, M.; Ciechanover, A.; Schwartz, A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue Oncogene 2000, 19, 5944-5950 (Pubitemid 32005376)
18. Narisawa-Saito, M.; Kiyono, T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins Cancer Sci. 2007, 98, 1505-1511
19. Boulet, G.; Horvath, C.; Vanden Broeck, D.; Sahebali, S.; Bogers, J. Human papillomavirus: E6 and E7 oncogenes Int. J. Biochem. Cell Biol. 2007, 39, 2006-2011
20. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S. R.; Huang, P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome Mol. Pharmacol. 2006, 70, 426-433
21. Bonfili, L.; Cecarini, V.; Amici, M.; Cuccioloni, M.; Angeletti, M.; Keller, J. N.; Eleuteri, A. M. Natural polyphenols as proteasome modulators and their role as anti-cancer compounds FEBS J. 2008, 275, 5512-5526
22. Cuccioloni, M.; Mozzicafreddo, M.; Bonfili, L.; Cecarini, V.; Eleuteri, A. M.; Angeletti, M. Natural occurring polyphenols as template for drug design. Focus on serine proteases Chem. Biol. Drug Des. 2009, 74, 1-15
23. Milacic, V.; Banerjee, S.; Landis-Piwowar, K. R.; Sarkar, F. H.; Majumdar, A. P.; Dou, Q. P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo Cancer Res. 2008, 68, 7283-7292
24. Mozzicafreddo, M.; Cuccioloni, M.; Bonfili, L.; Eleuteri, A. M.; Fioretti, E.; Angeletti, M. Antiplasmin activity of natural occurring polyphenols Biochim. Biophys. Acta 2008, 1784, 995-1001
25. Bogyo, M.; Shin, S.; McMaster, J. S.; Ploegh, H. L. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes Chem. Biol. 1998, 5, 307-320
26. Kessler, B. M.; Tortorella, D.; Altun, M.; Kisselev, A. F.; Fiebiger, E.; Hekking, B. G.; Ploegh, H. L.; Overkleeft, H. S. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits Chem. Biol. 2001, 8, 913-929
27. Marastoni, M.; Baldisserotto, A.; Trapella, C.; Gavioli, R.; Tomatis, R. Synthesis and biological evaluation of new vinyl ester pseudotripeptide proteasome inhibitors Eur. J. Med. Chem. 2006, 41, 978-984
28. Baldisserotto, A.; Marastoni, M.; Fiorini, S.; Pretto, L.; Ferretti, V.; Gavioli, R.; Tomatis, R. Vinyl ester-based cyclic peptide proteasome inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 1849-1854
29. Chauhan, D.; Hideshima, T.; Anderson, K. C. Targeting proteasomes as therapy in multiple myeloma Adv. Exp. Med. Biol. 2008, 615, 251-260
30. Baldisserotto, A.; Destro, F.; Vertuani, G.; Marastoni, M.; Gavioli, R.; Tomatis, R. N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors Bioorg. Med. Chem. 2009, 17, 5535-5540
31. Luker, G. D.; Pica, C. M.; Song, J.; Luker, K. E.; Piwnica-Worms, D. Imaging 26S proteasome activity and inhibition in living mice Nat. Med. 2003, 9, 969-973
32. Groll, M.; Huber, R. Purification, crystallization, and X-ray analysis of the yeast 20S proteasome Methods Enzymol. 2005, 398, 329-336
33. McElvain, S. M.; McMahon, R. E. Piperidine derivatives. 4-piperidone, 4-piperidinol and certain of their derivatives J. Am. Chem. Soc. 1949, 71, 3
34. Gavioli, R.; Vertuani, S.; Masucci, M. G. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors Int. J. Cancer 2002, 101, 532-538
35. Hendil, K. B.; Uerkvitz, W. The human multicatalytic proteinase: affinity purification using a monoclonal antibody J. Biochem. Biophys. Methods 1991, 22, 159-165
36. Belley, B. Massive thermostatins in isothermal density functional molecular dynamics simulations J. Chem. Phys. 1990, 50, 1
37. Groll, M.; Larionov, O. V.; Huber, R.; de Meijere, A. Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4576-4579
38. Groll, M.; Balskus, E. P.; Jacobsen, E. N. Structural analysis of spiro beta-lactone proteasome inhibitors J. Am. Chem. Soc. 2008, 130, 14981-1483
39. Ponder, J. W.; Case, D. A. Force fields for protein simulations Adv. Protein Chem. 2003, 66, 27-85
40. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relashionship: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55